(EXEL) Exelixis - Ratings and Ratios

Exelixis, Inc. (NASDAQ: EXEL) is a biotechnology company specializing in the development and commercialization of targeted therapies for oncology. Its portfolio includes approved drugs such as CABOMETYX (cabozantinib) for advanced renal cell carcinoma and COMETRIQ (cabozantinib) for metastatic medullary thyroid cancer. These products leverage the inhibition of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also markets COTELLIC (cobimetinib) for advanced melanoma and MINNEBRO (esaxerenone) for hypertension in Japan. Its pipeline includes zanzalintinib, a next-generation TKI targeting VEGF, MET, and TAM kinases; XL309, a USP1 inhibitor for BRCA-mutated tumors; XB010, an ADC targeting the 5T4 antigen; and XL495, a PKMYT1 inhibitor. Exelixis has established collaborations with major pharmaceutical companies, including Ipsen, Takeda, Roche, Bristol-Myers Squibb, and Merck. The company, founded in 1994 and headquartered in Alameda, California, has a market capitalization of ~$9.7 billion as of its latest reporting.

Over the next three months, EXEL is expected to maintain its upward momentum, supported by strong fundamentals and technical indicators. The stock is trading above its 20-day, 50-day, and 200-day SMAs, with the 20-day SMA crossing above the 50-day SMA, indicating bullish momentum. The ATR of 1.27 suggests moderate volatility. Fundamentally, the P/E ratio of 20.56, forward P/E of 16.45, and RoE of 23.23 highlight its profitability and growth potential. With a market cap of ~$9.7 billion and a P/S ratio of 4.60, EXEL is well-positioned for continued growth in the oncology sector.